Elevated levels of procoagulant microparticles in a patient with myocardial infarction, antiphospholipid antibodies and multifocal cardiac thrombosis

Circulating procoagulant microparticles (MP) are pathogenic markers of enhanced coagulability associated to a variety of disorders and released from stimulated vascular cells. When derived from endothelial cells, MP were found characteristic of thrombotic propensity in primary antiphospholipid syndrome (APS). The prothrombotic status of a patient with antiphospholipid antibodies (APL), a past history of mesenteric vein thrombosis and presenting myocardial infarction and extensive intracardiac thrombosis was examined by measurement of circulating procoagulant MP. MP of platelet and endothelial origins were highly elevated with respect to values detectable in patients with myocardial infarction and no history of APS (6- and 3-fold elevation, respectively) or in healthy volunteers (13- and 25-fold elevation, respectively). In this particular patient, with moderate APL titer, a drastic release of procoagulant MP could have contributed to thrombus growth and the development of extensive intracardiac thrombosis.

[1]  J. Freyssinet,et al.  Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. , 2000, Circulation.

[2]  S. Nomura,et al.  Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome , 2003, Thrombosis and Haemostasis.

[3]  J. Freyssinet,et al.  Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb‐IIIa antagonists , 2004, Journal of thrombosis and haemostasis : JTH.

[4]  J. Freyssinet,et al.  The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV-1 infection. , 1997, The Journal of clinical investigation.

[5]  C. O'connor,et al.  Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. , 2003, American heart journal.

[6]  D. Triplett Antiphospholipid antibodies : Diagnostic issues in thrombophilia , 2002 .

[7]  R. Nieuwland,et al.  Microparticles in cardiovascular diseases. , 2003, Cardiovascular research.

[8]  J. Freyssinet,et al.  Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. , 1999, Blood.

[9]  J. Freyssinet Cellular microparticles: what are they bad or good for? , 2003, Journal of thrombosis and haemostasis : JTH.

[10]  K. Preissner,et al.  Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  C. Cemin,et al.  Successful treatment of post-exertion acute myocardial infarction by primary angioplasty and stenting in a patient with antiphospholipid antibody syndrome , 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[12]  R. Nieuwland,et al.  Measuring circulating cell‐derived microparticles , 2004, Journal of thrombosis and haemostasis : JTH.

[13]  G. Hughes,et al.  Antiphospholipid antibodies , 1994, Clinical Reviews in Allergy.

[14]  H. Hod,et al.  Successful thrombolytic therapy for acute myocardial infarction in a patient with the antiphospholipid antibody syndrome. , 1991, American heart journal.

[15]  P. Daly,et al.  Elevated platelet-derived microparticle levels during unstable angina. , 1995, The Canadian journal of cardiology.

[16]  L. Horstman,et al.  High levels of circulating endothelial microparticles in patients with acute coronary syndromes. , 2003, American heart journal.

[17]  J. Freyssinet,et al.  Cellular microparticles: a disseminated storage pool of bioactive vascular effectors , 2004, Current opinion in hematology.

[18]  J. Piette,et al.  The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. , 1998, The Journal of clinical investigation.

[19]  J. Vermylen,et al.  Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease , 2003, Journal of thrombosis and haemostasis : JTH.

[20]  O. Morel,et al.  Protective effects of vitamin C on endothelium damage and platelet activation during myocardial infarction in patients with sustained generation of circulating microparticles , 2003, Journal of thrombosis and haemostasis : JTH.

[21]  F. Dignat-George,et al.  Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome , 2004, Thrombosis and Haemostasis.

[22]  F. Neumann,et al.  Platelet function in acute myocardial infarction treated with direct angioplasty. , 1996, Circulation.

[23]  M. Li,et al.  Different effects of various anti‐GPIIb‐IIIa agents on shear‐induced platelet activation and expression of procoagulant activity , 2003, Journal of thrombosis and haemostasis : JTH.

[24]  J. Freyssinet,et al.  Membrane microparticles: two sides of the coin. , 2005, Physiology.

[25]  G. Daggard,et al.  CORONARY ARTERY BYPASS GRAFT FAILURE—AN AUTOIMMUNE PHENOMENON? , 1986, The Lancet.

[26]  G. Grau,et al.  In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. , 1999, The Journal of clinical investigation.